HK1210720A1 - 大分子微球的製備技術 - Google Patents

大分子微球的製備技術

Info

Publication number
HK1210720A1
HK1210720A1 HK15111665.4A HK15111665A HK1210720A1 HK 1210720 A1 HK1210720 A1 HK 1210720A1 HK 15111665 A HK15111665 A HK 15111665A HK 1210720 A1 HK1210720 A1 HK 1210720A1
Authority
HK
Hong Kong
Prior art keywords
preparation
technology
macromolecular microspheres
microspheres
macromolecular
Prior art date
Application number
HK15111665.4A
Other languages
English (en)
Inventor
邁克爾．
．馬拉科夫
房芳
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of HK1210720A1 publication Critical patent/HK1210720A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
HK15111665.4A 2006-01-24 2009-10-05 大分子微球的製備技術 HK1210720A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76200206P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
HK1210720A1 true HK1210720A1 (zh) 2016-05-06

Family

ID=38197716

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111665.4A HK1210720A1 (zh) 2006-01-24 2009-10-05 大分子微球的製備技術

Country Status (13)

Country Link
US (7) US20070190163A1 (zh)
EP (1) EP1981483A1 (zh)
JP (2) JP5457680B2 (zh)
KR (5) KR20150001844A (zh)
CN (2) CN104758253A (zh)
AU (1) AU2007233349A1 (zh)
BR (1) BRPI0706947B8 (zh)
CA (2) CA2932997C (zh)
HK (1) HK1210720A1 (zh)
IL (2) IL193001A (zh)
RU (2) RU2464973C2 (zh)
WO (1) WO2007114881A1 (zh)
ZA (1) ZA200807133B (zh)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
KR20050085130A (ko) * 2002-11-22 2005-08-29 유 망 광범위 스펙트럼의 항-바이러스 치료제 및 예방제
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007114881A1 (en) 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
CN104774924B (zh) * 2006-09-18 2021-04-13 通用电气医疗集团生物科学公司 用玻璃覆盖的生物学试剂的制备
US20090098207A1 (en) * 2007-07-24 2009-04-16 Nexbio, Inc. Technology for the Preparation of Microparticles
CA2709071C (en) 2007-12-14 2016-11-15 Labogroup S.A.S. Delivering aerosolizable food products
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
KR101629154B1 (ko) 2008-06-13 2016-06-21 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2300083T3 (da) 2008-06-20 2013-07-22 Mannkind Corp Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
EP2344196B1 (en) * 2008-09-12 2018-11-14 University Court of The University of St Andrews Carbohydrate binding molecules
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EA201170950A1 (ru) * 2009-01-22 2012-02-28 Санофи Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
CN102711807A (zh) * 2009-11-06 2012-10-03 耐百生物制药有限公司 用于在呼吸道中进行治疗和预防的方法、化合物和组合物
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
BR112013020383A2 (pt) 2011-02-09 2017-06-13 Glaxosmithkline Llc formulações liofilizadas.
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9643996B2 (en) 2011-11-04 2017-05-09 Battelle Memorial Institute Processes for producing protein microparticles
US9034347B2 (en) * 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013096883A2 (en) 2011-12-23 2013-06-27 The Regents Of The University Of California Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
AU2013221230A1 (en) * 2012-02-17 2014-10-02 Ansun Biopharma, Inc. Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
MY171122A (en) 2012-05-29 2019-09-26 Parion Sciences Inc Dendrimer like amino amides processing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2014005107A2 (en) * 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
WO2014005103A2 (en) * 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
CN102757726B (zh) * 2012-08-07 2014-04-09 湖南罗比特化学材料有限公司 一种基于天然多羟基糖类制备的水性uv涂料及其方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US10828276B2 (en) 2012-11-28 2020-11-10 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
GEP20186903B (en) 2012-12-17 2018-10-25 Saiensis Ink Perion Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN103109798B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治红火蚁的生物农药制剂及其制备方法
CN103109799B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治斜纹夜蛾的生物农药制剂及其制备方法
CN103109800B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治小菜蛾的生物农药制剂及其制备方法
EP2968189A4 (en) * 2013-03-15 2016-11-16 Ansun Biopharma Inc METHOD FOR PRODUCING INJECTABLE PROTEIN MICROPARTICLE SUSPENSIONS
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
CN114848614A (zh) * 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10328128B2 (en) * 2014-09-17 2019-06-25 Ansun Biopharma, Inc. Treatment of infection by human enterovirus D68
DE102014114403A1 (de) * 2014-10-02 2016-04-07 Gerresheimer Regensburg Gmbh Stopfen zum Aufsetzen auf ein Anschlusselement einer medizinischen Spritze
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák
CN104523659A (zh) * 2015-01-19 2015-04-22 陈长潭 一种胸腺五肽吸入粉雾剂及其制备方法
CN106924715A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 特利加压素脂质体及其制备方法
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN106075403A (zh) * 2016-06-12 2016-11-09 暨南大学 一种胰岛素口服硒纳米制剂及其制备方法
IL305907A (en) 2016-07-01 2023-11-01 Univ Leland Stanford Junior conjugates for editing cell surface area is intended
KR20180007322A (ko) * 2016-07-11 2018-01-22 주식회사 삼양바이오팜 고분자 마이크로스피어의 연속 제조방법 및 이를 위한 장치
CA3031097A1 (en) * 2016-07-18 2018-01-25 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
DE102017104277A1 (de) * 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmukosales Verabreichungssystem für Idebenon
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
CN108853492A (zh) * 2018-07-25 2018-11-23 中国医学科学院生物医学工程研究所 治疗自身性免疫疾病的疫苗佐剂及其应用
CN109678964B (zh) * 2018-12-21 2022-02-25 陕西师范大学 一种利托菌素磁珠、制备方法及其应用
CN110664758B (zh) * 2019-10-15 2021-11-30 无锡市人民医院 Pai-cpt还原响应型双药递送纳米粒子的制备方法
CN110923628B (zh) * 2019-11-06 2021-11-26 南京理工大学 一种新型表面团簇分子的制备方法
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung
WO2021242751A1 (en) * 2020-05-28 2021-12-02 Hu Mickey Compositions and methods for treating sars-cov-2
CN112472664B (zh) * 2020-11-17 2022-02-25 中国矿业大学 一种基因靶向治疗的纳米马达-水凝胶体系制备方法
CA3237027A1 (en) * 2021-11-02 2023-05-11 Ansun Biopharma Inc. Das181 variant compositions
CN113893384B (zh) * 2021-11-08 2022-06-21 山东省科学院生物研究所 一种交联壳聚糖微球及其在创面止血修复材料中的应用
CN114377200B (zh) * 2022-01-12 2023-03-24 北京阅色科技发展中心(有限合伙) 面部注射填充用可生物降解亲水高分子微球及制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN115770232A (zh) * 2022-10-28 2023-03-10 苏州大学 一种地佐辛缓释微球及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5052558A (en) * 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5323907A (en) * 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5578709A (en) * 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO1998006279A1 (en) * 1996-08-09 1998-02-19 Gibson Suzanne M Heat-stable protein microparticles and no-shear process for producing same
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
KR20050085130A (ko) 2002-11-22 2005-08-29 유 망 광범위 스펙트럼의 항-바이러스 치료제 및 예방제
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
CN1826170B (zh) * 2003-07-18 2010-12-08 巴克斯特国际公司 通过受控相分离制备的小球形颗粒的制造方法、其用途和成分
CN102861325A (zh) 2003-11-10 2013-01-09 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
JP5634009B2 (ja) 2004-05-12 2014-12-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2007114881A1 (en) 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
US20090098207A1 (en) 2007-07-24 2009-04-16 Nexbio, Inc. Technology for the Preparation of Microparticles

Also Published As

Publication number Publication date
CA2639925A1 (en) 2007-10-11
CA2932997C (en) 2019-07-30
IL240268A0 (en) 2015-09-24
JP5457680B2 (ja) 2014-04-02
US10583086B2 (en) 2020-03-10
RU2008134282A (ru) 2010-02-27
WO2007114881A1 (en) 2007-10-11
JP2009524667A (ja) 2009-07-02
ZA200807133B (en) 2009-05-27
JP6063239B2 (ja) 2017-01-18
KR20160147067A (ko) 2016-12-21
KR20150001844A (ko) 2015-01-06
BRPI0706947A2 (pt) 2011-04-12
BRPI0706947B1 (pt) 2021-02-09
CN101404980A (zh) 2009-04-08
US20070190163A1 (en) 2007-08-16
KR102180849B1 (ko) 2020-11-20
RU2012131203A (ru) 2014-01-20
CA2639925C (en) 2016-07-12
CA2932997A1 (en) 2007-10-11
US20140134150A1 (en) 2014-05-15
KR102109867B1 (ko) 2020-05-13
BRPI0706947B8 (pt) 2021-05-25
AU2007233349A1 (en) 2007-10-11
JP2013064010A (ja) 2013-04-11
US20180071219A1 (en) 2018-03-15
RU2628807C2 (ru) 2017-08-22
IL193001A (en) 2015-08-31
KR20170091184A (ko) 2017-08-08
US20150290134A1 (en) 2015-10-15
RU2464973C2 (ru) 2012-10-27
KR101787939B1 (ko) 2017-10-18
KR20200052386A (ko) 2020-05-14
CN104758253A (zh) 2015-07-08
BRPI0706947A8 (pt) 2019-01-29
US20200197310A1 (en) 2020-06-25
US20120116062A1 (en) 2012-05-10
KR20080090525A (ko) 2008-10-08
EP1981483A1 (en) 2008-10-22
US20100166874A1 (en) 2010-07-01
US8623419B2 (en) 2014-01-07
KR101501780B1 (ko) 2015-03-16
IL193001A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
IL240268A0 (en) Technology for the preparation of macromolecular microspheres
TWI372079B (en) Microspheres
ZA200900142B (en) Microspheres
ZA200807758B (en) Microspheres
GB0711952D0 (en) Microspheres
GB0624963D0 (en) Derivatives of 188-Glycyrrhetinic Acid
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
GB0705854D0 (en) Methods of construction
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
ZA200900927B (en) Glyoxalation of vinylmide polymer
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
PL2171061T3 (pl) Preparat esterazy
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
GB0623897D0 (en) Pharmaceutical composition of memantine
HUP0600117A2 (en) Structure of road
EP1997114A4 (en) COMPOSITIONS OF MATERIAL: SYSTEM II
EP2100345A4 (en) ANTENNA OF PARALLEL ANNULAR TYPE
TWM301105U (en) Improved structure of socket
GB201114396D0 (en) Location of basesation
GB0622341D0 (en) Novel compounds and methods for their preparation
TWM298442U (en) Improved structure of sprinkle-nozzle for fire-extinguisher
TWM311768U (en) Improved structure of A-ladder
GB0612370D0 (en) Uses of (S)-clenbuterol
GB0614601D0 (en) Microspheres
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines